Skip to main content Accessibility help
×
Hostname: page-component-77c89778f8-9q27g Total loading time: 0 Render date: 2024-07-17T10:24:51.760Z Has data issue: false hasContentIssue false

6 - Screening tests

Published online by Cambridge University Press:  04 August 2010

Thomas B. Newman
Affiliation:
University of California, San Francisco
Michael A. Kohn
Affiliation:
University of California, San Francisco
Get access

Summary

Introduction

You may wonder why we have a separate chapter on screening tests. After all, now that you have learned about sensitivity, specificity, likelihood ratios, Receiver Operating Characteristic curves and so forth, it seems like you should be well equipped to evaluate screening tests. However, whereas diagnostic tests are done on sick people to determine the cause of their symptoms, screening tests are generally done on healthy people with a low prior probability of disease. The problem of false positives and possible harms of unnecessary treatment looms larger. The questions of whether the patient benefits from being diagnosed and whether this benefit justifies the possible harms and costs of the test are more salient for screening. Finally, because decisions about screening are often made at the population level, political and other factors may be more influential. Thus, in this chapter, we focus explicitly on the question of whether doing the test improves health, not just whether it gives the right answer, and we pay particular attention to biases and nonmedical factors that can lead to excessive screening.

Definition and types of screening

Our favorite definition of screening is that suggested by Eddy (1991): “the application of a test to detect a potential disease or condition in people with no known signs or symptoms of that disease or condition.” The “test” being applied may be a laboratory test or x-ray, or it may be nothing more than a standard series of questions, as long as the goal is to detect a disease or condition of which the patient has no known symptoms.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Barton, M., Morley, D., et al. (2004). “Decreasing women's anxieties after abnormal mammograms: a controlled trial.” J Natl Cancer Inst 96: 529–38.CrossRefGoogle ScholarPubMed
Black, W. C., Haggstrom, D. A., et al. (2002). “All-cause mortality in randomized trials of cancer screening.” J Natl Cancer Inst 94(3): 167–73.CrossRefGoogle ScholarPubMed
Black, W. C., and Welch, H. G. (1997). “Screening for disease.” AJR Am J Roentgenol 168(1): 3–11.CrossRefGoogle ScholarPubMed
Braveman, P., and Tarimo, E. (1994). Screening in Primary Health Care: Setting Priorities with Limited Resources. Geneva, World Health Organization.Google Scholar
Daniels, N. (1986). “Why saying no to patients in the United States is so hard. Cost containment, justice, and provider autonomy.” N Engl J Med 314(21): 1380–3.CrossRefGoogle ScholarPubMed
,Early Breast Cancer Trialists' Collaborative Group (2000). “Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials.” Lancet 355(9217): 1757–70.CrossRefGoogle Scholar
Eddy, D. (1991). Common Screening Tests. Philadelphia, PA, American College of Physicians.Google Scholar
Eddy, D. M. (1997). “Breast cancer screening in women younger than 50 years of age: what's next?Ann Intern Med 127(11): 1035–6.CrossRefGoogle ScholarPubMed
Epstein, A. E., Hallstrom, A. P., et al. (1993). “Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST).” JAMA 270(20): 2451–5.CrossRefGoogle Scholar
Ernster, V. L. (1997). “Mammography screening for women aged 40 through 49–a guidelines saga and a clarion call for informed decision making.” Am J Public Health 87(7): 1103–6.CrossRefGoogle Scholar
Feinstein, A. R., Sosin, D. M., et al. (1985). “The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer.” N Engl J Med 312(25): 1604–8.CrossRefGoogle Scholar
Fyro, K., and Bodegard, G. (1987). “Four-year follow-up of psychological reactions to false positive screening tests for congenital hypothyroidism.” Acta Paediatr Scand 76(1): 107–14.CrossRefGoogle ScholarPubMed
Guyatt, G., Rennie, D., et al. (2008). Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 2nd Edition. New York, NY, McGraw Hill Medical, pp. 113–143.Google Scholar
Haynes, R. B., Sackett, D. L., et al. (1978). “Increased absenteeism from work after detection and labeling of hypertensive patients.” N Engl J Med 299(14): 741–4.CrossRefGoogle ScholarPubMed
,Health Plan Employer Data and Information Set (2009). “The Health Plan Employer Data and Information Set (HEDIS®).” Available from: http://www.ncqa.org/tabid/784/Default.aspx. Accessed 10/3/08.
Herman, C. R., Gill, H. K, et al. (2002). “Screening for preclinical disease: test and disease characteristics.” AJR Am J Roentgenol 179(4): 825–31.CrossRefGoogle ScholarPubMed
Law, J., and Faulkner, K. (2001). “Cancers detected and induced, and associated risk and benefit, in a breast screening programme.” Br J Radiol 74(888): 1121–7.CrossRefGoogle Scholar
Lee, T., and Brennan, T. (2002). “Direct-to-consumer marketing of high-technology screening tests.” N Engl J Med 346(7): 529–531.CrossRefGoogle ScholarPubMed
Marantz, P. R. (1990). “Blaming the victim: the negative consequence of preventive medicine.” Am J Public Health 80(10): 1186–7.CrossRefGoogle ScholarPubMed
Marcus, P. M., Bergstralh, E. J., et al. (2000). “Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up.” J Natl Cancer Inst 92(16): 1308–16.CrossRefGoogle ScholarPubMed
Mariner, W. K. (1995). “Rationing health care and the need for credible scarcity: why Americans can't say no.” Am J Public Health 85(10): 1439–45.CrossRefGoogle ScholarPubMed
Moore, T. J. (1995). Deadly Medicine: Why Tens of Thousands of Heart Patients Died in America's Worst Drug Disaster. New York, Simon & Schuster.Google Scholar
Newman, T. B. (2003). “The power of stories over statistics.” Br Med J 327(7429): 1424–7.CrossRefGoogle ScholarPubMed
Olivotto, I. A., Truong, P. T., et al. (2003). “Staging reclassification affects breast cancer survival.” J Clin Oncol 21(23): 4467–8.CrossRefGoogle ScholarPubMed
Otto, S. J., Schroder, F. H., et al. (2004). “Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: self-selection bias?J Med Screen 11(2): 89–92.CrossRefGoogle ScholarPubMed
Riggs, B. L., Hodgson, S. F., et al. (1990). “Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.” N Engl J Med 322(12): 802–9.CrossRefGoogle ScholarPubMed
Rubin, S. M., and Cummings, S. R. (1992). “Results of bone densitometry affect women's decisions about taking measures to prevent fractures.” Ann Intern Med 116(12 Pt 1): 990–5.CrossRefGoogle ScholarPubMed
Schwartz, L. M., Woloshin, S., et al. (2004). “Enthusiasm for cancer screening in the United States.” JAMA 291(1): 71–8.CrossRefGoogle ScholarPubMed
Welch, H. G. (2004). Should I Be Tested for Cancer? Maybe Not, and Here's Why. Berkeley, CA, University of California Press.Google Scholar
,World Health Organization (1980). “W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators.” Lancet 2(8191): 379–85.Google Scholar
Woodward, W. A., Strom, E. A., et al. (2003). “Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival.” J Clin Oncol 21(17): 3244–8.CrossRefGoogle ScholarPubMed
Ashton, H. A., Buxton, M. J., et al. (2002). “The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial.” Lancet 360(9345): 1531–9.Google ScholarPubMed
Henschke, C. I., Yankelevitz, D. F., et al. (2006). “Survival of patients with stage I lung cancer detected on CT screening.” N Engl J Med 355(17): 1763–71.Google Scholar
Mastroiacovo, P., Bertollini, R., et al. (1992). “Survival of children with Down syndrome in Italy.” Am J Med Genet 42(2): 208–12.CrossRefGoogle ScholarPubMed
Torres, C. F., Rebsamen, S, et al. (1994). “Surveillance scanning of children with medulloblastomaN Engl J Med 330(13): 892–5.CrossRefGoogle ScholarPubMed
Barton, M., Morley, D., et al. (2004). “Decreasing women's anxieties after abnormal mammograms: a controlled trial.” J Natl Cancer Inst 96: 529–38.CrossRefGoogle ScholarPubMed
Black, W. C., Haggstrom, D. A., et al. (2002). “All-cause mortality in randomized trials of cancer screening.” J Natl Cancer Inst 94(3): 167–73.CrossRefGoogle ScholarPubMed
Black, W. C., and Welch, H. G. (1997). “Screening for disease.” AJR Am J Roentgenol 168(1): 3–11.CrossRefGoogle ScholarPubMed
Braveman, P., and Tarimo, E. (1994). Screening in Primary Health Care: Setting Priorities with Limited Resources. Geneva, World Health Organization.Google Scholar
Daniels, N. (1986). “Why saying no to patients in the United States is so hard. Cost containment, justice, and provider autonomy.” N Engl J Med 314(21): 1380–3.CrossRefGoogle ScholarPubMed
,Early Breast Cancer Trialists' Collaborative Group (2000). “Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials.” Lancet 355(9217): 1757–70.CrossRefGoogle Scholar
Eddy, D. (1991). Common Screening Tests. Philadelphia, PA, American College of Physicians.Google Scholar
Eddy, D. M. (1997). “Breast cancer screening in women younger than 50 years of age: what's next?Ann Intern Med 127(11): 1035–6.CrossRefGoogle ScholarPubMed
Epstein, A. E., Hallstrom, A. P., et al. (1993). “Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST).” JAMA 270(20): 2451–5.CrossRefGoogle Scholar
Ernster, V. L. (1997). “Mammography screening for women aged 40 through 49–a guidelines saga and a clarion call for informed decision making.” Am J Public Health 87(7): 1103–6.CrossRefGoogle Scholar
Feinstein, A. R., Sosin, D. M., et al. (1985). “The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer.” N Engl J Med 312(25): 1604–8.CrossRefGoogle Scholar
Fyro, K., and Bodegard, G. (1987). “Four-year follow-up of psychological reactions to false positive screening tests for congenital hypothyroidism.” Acta Paediatr Scand 76(1): 107–14.CrossRefGoogle ScholarPubMed
Guyatt, G., Rennie, D., et al. (2008). Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 2nd Edition. New York, NY, McGraw Hill Medical, pp. 113–143.Google Scholar
Haynes, R. B., Sackett, D. L., et al. (1978). “Increased absenteeism from work after detection and labeling of hypertensive patients.” N Engl J Med 299(14): 741–4.CrossRefGoogle ScholarPubMed
,Health Plan Employer Data and Information Set (2009). “The Health Plan Employer Data and Information Set (HEDIS®).” Available from: http://www.ncqa.org/tabid/784/Default.aspx. Accessed 10/3/08.
Herman, C. R., Gill, H. K, et al. (2002). “Screening for preclinical disease: test and disease characteristics.” AJR Am J Roentgenol 179(4): 825–31.CrossRefGoogle ScholarPubMed
Law, J., and Faulkner, K. (2001). “Cancers detected and induced, and associated risk and benefit, in a breast screening programme.” Br J Radiol 74(888): 1121–7.CrossRefGoogle Scholar
Lee, T., and Brennan, T. (2002). “Direct-to-consumer marketing of high-technology screening tests.” N Engl J Med 346(7): 529–531.CrossRefGoogle ScholarPubMed
Marantz, P. R. (1990). “Blaming the victim: the negative consequence of preventive medicine.” Am J Public Health 80(10): 1186–7.CrossRefGoogle ScholarPubMed
Marcus, P. M., Bergstralh, E. J., et al. (2000). “Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up.” J Natl Cancer Inst 92(16): 1308–16.CrossRefGoogle ScholarPubMed
Mariner, W. K. (1995). “Rationing health care and the need for credible scarcity: why Americans can't say no.” Am J Public Health 85(10): 1439–45.CrossRefGoogle ScholarPubMed
Moore, T. J. (1995). Deadly Medicine: Why Tens of Thousands of Heart Patients Died in America's Worst Drug Disaster. New York, Simon & Schuster.Google Scholar
Newman, T. B. (2003). “The power of stories over statistics.” Br Med J 327(7429): 1424–7.CrossRefGoogle ScholarPubMed
Olivotto, I. A., Truong, P. T., et al. (2003). “Staging reclassification affects breast cancer survival.” J Clin Oncol 21(23): 4467–8.CrossRefGoogle ScholarPubMed
Otto, S. J., Schroder, F. H., et al. (2004). “Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: self-selection bias?J Med Screen 11(2): 89–92.CrossRefGoogle ScholarPubMed
Riggs, B. L., Hodgson, S. F., et al. (1990). “Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.” N Engl J Med 322(12): 802–9.CrossRefGoogle ScholarPubMed
Rubin, S. M., and Cummings, S. R. (1992). “Results of bone densitometry affect women's decisions about taking measures to prevent fractures.” Ann Intern Med 116(12 Pt 1): 990–5.CrossRefGoogle ScholarPubMed
Schwartz, L. M., Woloshin, S., et al. (2004). “Enthusiasm for cancer screening in the United States.” JAMA 291(1): 71–8.CrossRefGoogle ScholarPubMed
Welch, H. G. (2004). Should I Be Tested for Cancer? Maybe Not, and Here's Why. Berkeley, CA, University of California Press.Google Scholar
,World Health Organization (1980). “W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators.” Lancet 2(8191): 379–85.Google Scholar
Woodward, W. A., Strom, E. A., et al. (2003). “Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival.” J Clin Oncol 21(17): 3244–8.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Screening tests
  • Thomas B. Newman, University of California, San Francisco, Michael A. Kohn, University of California, San Francisco
  • Book: Evidence-Based Diagnosis
  • Online publication: 04 August 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511759512.007
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Screening tests
  • Thomas B. Newman, University of California, San Francisco, Michael A. Kohn, University of California, San Francisco
  • Book: Evidence-Based Diagnosis
  • Online publication: 04 August 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511759512.007
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Screening tests
  • Thomas B. Newman, University of California, San Francisco, Michael A. Kohn, University of California, San Francisco
  • Book: Evidence-Based Diagnosis
  • Online publication: 04 August 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511759512.007
Available formats
×